Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05970640 · ClinicalTrials.gov registry record · Phase 1
A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
A Phase 1 study of Obesity and Non-alcoholic Fatty Liver Disease, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 12
- Study locations
NCT05970640 is a Phase 1 study of Obesity and Non-alcoholic Fatty Liver Disease that has completed, run by Boehringer Ingelheim. The registered enrollment target is 64 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (92% lower). The trial reports 12 study locations across 7 states.
The verdict
NCT05970640, a Phase 1 study of Obesity and Non-alcoholic Fatty Liver Disease, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 12
- Study locations
Study Summary
This study is open to adults with overweight or obesity who also have fatty liver disease. The purpose of this study is to find the highest dose of BI 3006337 that people with overweight or obesity and with fatty liver disease can tolerate. Participants are divided into 4 groups of equal size randomly, which means by chance. Different doses of BI 3006337 are given to participants in each group. Participants in each group receive an injection of either BI 3006337 or placebo once a week. Placebo injections look like BI 3006337 injections but do not contain any medicine. Participants are in the study for about 4 months. During this time, they visit the study site 18 times. Three of the visits include overnight stays at the study site. The doctors check the health of the participants and note any health problems that could have been caused by BI 3006337.
Conditions Studied
Interventions
- DRUG BI 3006337
- DRUG Placebo matching BI 3006337
Study Locations (12)
California
- Velocity Clinical Research-Chula Vista - Chula Vista
- Velocity Clinical Research-La Mesa-69117 - La Mesa
- Catalina Research Institute, LLC-Montclair-49051 - Montclair
Texas
- The Liver Institute at Methodist Dallas - Dallas
- American Research Corporation at the Texas Liver Institute - San Antonio
- Endeavor Clinical Trials - San Antonio
Florida
- Accel Research Sites-Deland-67606 - DeLand
- Floridian Clinical Research-Miami Lakes-68368 - Miami Lakes
Georgia
- iResearch Atlanta - Decatur
Ohio
- Centricity Research-Columbus-68879 - Columbus
Tennessee
- AMR Knoxville - Knoxville
Utah
- Velocity Clinical Research-West Jordan-69043 - West Jordan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-08-14 |
| Est. Completion | 2024-11-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05970640
The ClinicalTrials.gov registry entry for NCT05970640 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (92% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which BI 3006337 is the first listed.
NCT05970640 reports 12 study locations spanning 7 distinct geographic areas - top geographies include California, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT05970640 about?
NCT05970640 is a clinical study titled "A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease". This study is open to adults with overweight or obesity who also have fatty liver disease. The purpose of this study is to find the highest dose of BI 3006337 that people with overweight or obesity and with fatty liver disease can tolerate. Participants are divided into 4 groups of equal size rando...
What is the current status of trial NCT05970640?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2023-08-14. Estimated completion is 2024-11-07.
What conditions does trial NCT05970640 study?
This clinical trial studies the following conditions: Obesity, Non-alcoholic Fatty Liver Disease.
What interventions are being tested in trial NCT05970640?
The interventions under investigation include: BI 3006337 (DRUG), Placebo matching BI 3006337 (DRUG).
Who is sponsoring clinical trial NCT05970640?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05970640 being conducted?
This trial has 12 study locations across California, Florida, Georgia, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.